South Sudan Medicine Import Tax Review: Maxicare Urges Action

• Private healthcare providers in South Sudan, including Maxicare Medical and Surgical Complex, are raising concerns about high taxes and import costs on medicines and medical equipment.
• Dr. Shakir Thomas Eluzia called for a review of these charges, warning they threaten facility sustainability and lead to increased patient fees.
• The issue highlights the critical balance between government revenue generation and ensuring essential healthcare remains affordable for citizens.
• The Transitional National Legislative Assembly is urged to scrutinize financial and tax laws affecting healthcare, potentially considering targeted tax relief for essential medical supplies.
• Beyond tax reform, increased transparency in health spending and stronger anti-corruption measures in the pharmaceutical supply chain are deemed crucial for patient safety and effective care.

The Transitional National Legislative Assembly bears a significant responsibility to scrutinize financial and tax laws that impact the healthcare sector.

Access to affordable healthcare and essential medicines remains a significant challenge for citizens in South Sudan. Private medical facilities and pharmacies in the nation contend with a multitude of financial burdens, including various taxes, customs charges, import costs, and regulatory compliance expenses, all of which contribute to elevated prices for patients. Medicines are considered essential goods, not luxury items, and any increase in the cost of importing pharmaceutical supplies, medical equipment, or general medicines ultimately places an additional financial strain on those seeking treatment.

These concerns were recently brought to light in an Eye Radio report published on September 21, 2026, which detailed anxieties expressed by private healthcare providers regarding the financial environment. Dr. Shakir Thomas Eluzia, who heads the Maxicare Medical and Surgical Complex, publicly advocated for a comprehensive review of the taxes and charges imposed on healthcare facilities, with a particular focus on those affecting imported medicines and medical equipment. He underscored the potential for high operating costs to jeopardize the long-term viability of private health institutions and warned that these expenses could translate into increased charges for patients.

This intervention by Dr. Eluzia highlights a critical dilemma: balancing the government's need for revenue generation with the imperative of ensuring essential healthcare remains accessible and affordable for the populace. While taxation is a fundamental source of government income, intended to fund vital public services like healthcare and education, the current framework in South Sudan prompts questions about its appropriateness for such a crucial sector. The core issue is not the necessity of taxation itself, but rather whether the existing tax and regulatory structure adequately serves the public interest in healthcare.

A responsible tax policy should aim to generate public revenue without rendering essential medicines and medical services prohibitively expensive for ordinary citizens. The government requires domestic revenue to finance national development initiatives and bolster public institutions. Consequently, there is a pressing need to scrutinize the taxes, customs duties, and other charges levied on medicines, pharmaceutical supplies, and medical equipment to ascertain if they are unnecessarily inflating treatment costs within South Sudan's healthcare system. This review is crucial for addressing South Sudan healthcare taxation challenges.

The Transitional National Legislative Assembly bears a significant responsibility to scrutinize financial and tax laws that impact the healthcare sector. The legislature should actively consider implementing targeted tax relief or exemptions for essential medicines and critical medical equipment where appropriate. Such measures would not signify an abandonment of taxation but rather an adaptation of the tax system to acknowledge the public interest and the indispensable nature of healthcare, directly addressing South Sudan medicine import tax review.

Furthermore, revenue collection must be accompanied by robust transparency and accountability mechanisms. Taxpayers have a legitimate right to understand how much public money is allocated to healthcare, precisely where it is spent, and the outcomes it achieves. Therefore, the government should enhance the transparency of health budgets and expenditure reports, including detailed allocations for medicines, medical equipment, health facilities, and healthcare workers. Strengthening parliamentary oversight and independent auditing, with audit findings made publicly accessible, is also vital for ensuring responsible fiscal management.

While tax reform is a crucial component, it alone cannot resolve all the challenges confronting the healthcare sector in South Sudan. Equally important is a strengthened commitment to combating corruption. The government must enhance its oversight across the entire pharmaceutical supply chain, encompassing the importation, registration, distribution, and sale of medicines. This is critical to prevent counterfeit, expired, unregistered, unlicensed, or substandard medicines from entering the market, which pose severe risks to public health.

Corruption within medicine procurement, customs procedures, licensing, registration, and inspection processes can have life-threatening consequences. It is imperative that individuals found responsible for bribery, fraudulent practices, or deliberate violations of health regulations face appropriate legal repercussions. Ultimately, patients require more than just affordable medicines; they need assurances that the medicines they receive are safe, effective, and of high quality. Addressing these systemic issues, alongside a South Sudan medicine import tax review, is fundamental to improving healthcare outcomes.

Lawyers advising healthcare providers or pharmaceutical companies in South Sudan should monitor proposed tax reforms and regulatory changes concerning medicine imports and healthcare facility operations. Compliance officers need to be aware of potential changes in import duties, licensing requirements, and increased scrutiny on anti-corruption measures in the pharmaceutical supply chain.

Source: Original reporting via Eye Radio